If You Invested in LONGEVITY HEALTH HLDGS (XAGE)

Longevity Health Holdings, Inc. (Nasdaq: XAGE) is a company focused on human longevity and healthy aging. According to its public disclosures, Longevity concentrates on the latest scientific advances in regenerative bio-aesthetics, diagnostics, and nutrition, with products aimed at helping people look and feel their best at any age.

The company describes itself as a bio-aesthetics and longevity business that develops and markets products using regenerative technologies for skin and hair health. Longevity trades under the ticker symbol XAGE and has highlighted a strategy that connects aesthetic care with broader healthy aging themes, including diagnostic testing and prospective expansion into nutrition.

Business focus and product technologies

Longevity states that it is focused on technologically innovative and clinically oriented products in regenerative bio-aesthetics, diagnostics, and nutrition. Its disclosures describe two regenerative technologies that are part of its commercial portfolio for skin and hair health:

• Carmell Secretome™, described as a blend of growth factors, proteins, peptides and bio-lipids derived from allogeneic human platelets, the body’s principal cells responsible for healing and regeneration.
• Elevai Exosomes™, which are described as exosomes derived from human umbilical mesenchymal stem cells and noted as containing a greater number of proteins than exosomes from non-stem cell sources.

These technologies are positioned by the company within the broader theme of regenerative bio-aesthetics, with an emphasis on supporting skin and hair health as part of healthy aging.

Strategic direction and corporate development

Longevity has communicated a strategy that links bio-aesthetic products with diagnostics and nutrition under a healthy aging framework. In its public statements, the company has referenced a corporate rebranding and acquisition strategy aimed at building a footprint in diagnostics to create synergies with its existing bio-aesthetic portfolio and contemplated expansion into nutrition.

The company has disclosed acquisitions of Carmell Therapeutics and Elevai Skincare, which align with its regenerative bio-aesthetics focus. Longevity has also described a planned combination with 20/20 BioLabs, Inc. (20/20), a business that develops and commercializes laboratory tests for early detection and proactive management of chronic disease risk, including a multi-cancer early detection blood test (OneTest™) and a planned blood test for monitoring chronic inflammation. These disclosures illustrate how Longevity seeks to connect diagnostics with its aesthetic and longevity offerings.

In addition, Longevity announced a subsequent definitive merger agreement with True Health Inc., which operates under the THPlasma brand and runs plasma collection centers in the Northeast United States. The company has described this proposed transaction as an all-stock merger intended to combine Longevity with a plasma collection business that has long-term partnerships and guaranteed sales offtake agreements. A later Form 8-K filing reported that the merger agreement with True Health was terminated after the transaction was not consummated by a specified date, and no termination fee was payable by either party.

Diagnostics and healthy aging positioning

Through its announced merger agreement with 20/20, Longevity outlined a strategy to address chronic disease risk and healthy aging under the banner “Healthy Aging, Inside and Out™.” 20/20’s business, as described in Longevity’s news releases, includes a CLIA-licensed, CAP-accredited laboratory, the OneTest™ multi-cancer early detection blood test, and initiatives to offer testing in non-traditional settings such as homes and retail locations. Longevity has indicated that it plans to offer 20/20 diagnostic tests to its network of physicians to help design patient-specific bio-aesthetic protocols based on healthy aging, and to offer skincare products to 20/20’s customer base.

These disclosures show how Longevity frames its role at the intersection of regenerative aesthetics and diagnostic testing, with the goal of supporting both external appearance and internal markers of health as part of longevity-focused care.

Capital markets and listing status

Longevity’s common stock has traded on the Nasdaq Capital Market under the symbol XAGE. The company has reported actions taken in connection with its listing status and capital structure. In one announcement, Longevity described completing a 1-for-30 reverse stock split of its common stock, with trading on a split-adjusted basis on Nasdaq beginning under the existing ticker symbol XAGE. The company has also disclosed that a Nasdaq Hearings Panel granted it an exception to allow continued listing while it worked to complete its proposed merger with 20/20 and demonstrate compliance with Nasdaq’s initial listing rules for the combined company.

Subsequently, a Form 25 filing by Nasdaq Stock Market LLC indicated the removal of Longevity Health Holdings, Inc.’s common stock and warrants from listing and registration under Section 12(b) of the Securities Exchange Act of 1934 on the Nasdaq Stock Market. This Form 25 is a notification of removal from listing and/or registration and confirms that Nasdaq took action to strike the class of securities from listing. The filing does not, by itself, describe whether or how the securities may trade on other venues.

Financing activities

Longevity has disclosed the use of an at-the-market (ATM) equity offering facility to raise capital. In one news release, the company reported the sale of shares of its common stock through its ATM program, with gross proceeds prior to fees and expenses. The company stated that, based on certain assumptions, this financing extended its cash runway into a future fiscal period, and characterized the transaction as part of strengthening its balance sheet while pursuing its merger and product strategies.

Mergers, acquisitions and transaction updates

Public communications from Longevity describe several transaction-related milestones:

• An executed merger agreement with 20/20 BioLabs, Inc., under which 20/20 would become a wholly owned subsidiary of Longevity following closing, subject to specified conditions and approvals.
• A description of expected ownership percentages of the combined company’s equity between pre-merger Longevity stockholders and pre-merger 20/20 stockholders, and expectations regarding revenue and operational savings following the merger.
• Plans to use the combined company’s capabilities to address chronic disease and healthy aging, including cross-marketing of diagnostic tests and skincare products.
• A later merger agreement with True Health Inc. (THPlasma) and an amendment to that agreement, which adjusted the number of merger and earnout shares based on a defined market price formula.
• A subsequent Form 8-K reporting that Longevity provided notice of termination of the merger agreement with True Health after the merger was not consummated by the contractual outside date, with no termination fee payable.

These disclosures indicate that Longevity has actively pursued corporate combinations to expand its presence in diagnostics and, at one point, in plasma collection, while also making adjustments when transactions did not proceed to closing.

Regulatory filings and risk disclosures

Longevity’s news releases and SEC filings contain extensive forward-looking statement disclaimers and references to risk factors. The company directs investors to its Annual Report on Form 10-K and other SEC reports for detailed risk factor discussions, including risks related to completing mergers, maintaining exchange listings, obtaining regulatory approvals, managing expenses, realizing anticipated synergies, and obtaining additional capital.

Investors researching XAGE can review the company’s Forms 10-K, 10-Q, 8-K, and transaction-related registration statements and proxy materials filed with the U.S. Securities and Exchange Commission for more detailed information on its operations, strategy, and risk profile.